Thus, the potential mechanism by which PIM-1 affects sensitivity to the chemotherapy drug erlotinib or the expression of pancreatic cancer stem cell markers in pancreatic cancer may be by regulating the EGFR signalling pathway. Here, PIM1 is linked to pancreatic neoplasm.